Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis

Kristian Reich; Mark Lebwohl; Carle Paul; Mads Ropke; Monika Rosen; Klaus Hansen

doi:10.25251/skin.2.supp.1

Kristian Reich
Mark Lebwohl
Carle Paul
Mads Ropke
Monika Rosen
Klaus Hansen

Keywords

psoriasis, brodalumab, clinical trial

Abstract

Abstract not available.

This study was supported by Amgen/AstraZeneca. This poster was sponsored b y LEO Pharma.

Poster PDF

Published

Feb 23, 2018

DOI https://doi.org/10.25251/skin.2.supp.1

How to Cite

Reich, K., Lebwohl, M., Paul, C., Ropke, M., Rosen, M., & Hansen, K. (2018). Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis. SKIN The Journal of Cutaneous Medicine, 2(S1), S1. https://doi.org/10.25251/skin.2.supp.1

Issue

Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

April W. Armstrong, Mark Lebwohl, Jerry Bagel, Todd Schlesinger, Subhashis Banerjee, Renata M. Kisa, Thomas Scharnitz, Kim Hoyt, Bruce Strober, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Kristian Reich, Andrew Blauvelt, Diamant Thaci, Craig Leonardi, Yves Poulin, Daniel Burge, Luke Peterson, Catherine Arendt, Alice B Gottlieb, Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Andrew Blauvelt, Kristian Reich, Mark Lebwohl, Daniel Burge, Catherine Arendt, Luke Peterson, Robert Rolleri, Alice Gottlieb, Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Matthias Augustin, Jolanta Weglowska, Mark Lebwohl, Carle Paul, Vincent Piquet, Howard Sofen, Andrew Blauvelt, Daniel Burge, Luke Peterson, Janice Drew, Robert Rollen, Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Mark Lebwohl, Darrell Rigel, Todd Schlesinger, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Leon Kircik, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Comparison of patient and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area, among patients with Actinic Keratosis treated with tirbanibulin in community practices across U.S. , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Kristian Reich , April Armstrong , Yaowei Zhu, Megan Miller, Yin You, Yaung-Kaung Shen, Ya-Wen Yang, Peter Foley, Christopher Griffiths, Bruce Strober , Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Mark Lebwohl, Linda Stein Gold, Melinda J. Gooderham, Kim A. Papp, Laura K. Ferris, David N. Adam, H. Chih-ho Hong, Leon H. Kircik, Matthew Zirwas, Patrick Burnett, Robert Higham, Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Linda Stein Gold, Christopher E Griffiths, Anna M Tallman, Philip M Brown, Mark Lebwohl, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin Li, Thomas Eckmann, Baojin Zhu, William Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt, 6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Linda Stein Gold, Mark Lebwohl, Robert Bissonnette, Bruce Strober, Anna M Tallman, Philip M Brown, Stephen C Piscitelli, David S Rubenstein, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

<< < 4 5 6 7 8 9 10 11 12 13 > >>

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)